Kelfer250 mg
Capsule
Deferiprone
Cipla Limited
Product Code : 8932
10% Off
Best PriceTk
/
1
Medicine overview
Indications of Kelfer 250 mg
Kelfer 250 mg is indicated for the treatment of iron overload patients with thalassemia major when deferoxamine therapy is contraindicated or inadequate. Kelfer 250 mg therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassemia.
Theropeutic Class
Antidote preparations
Pharmacology
Kelfer 250 mg is a chelating agent with an affinity for ferric ion (iron III). Kelfer 250 mg binds with ferric ions to form neutral 3:1 (Kelfer 250 mg:iron) complexes that are stable over a wide range of pH values. Kelfer 250 mg has a lower binding affinity for other metals such as copper, aluminum and zinc than for iron.
Dosage & Administration of Kelfer 250 mg
Adult: 25 mg/kg tid. Doses >100 mg/kg daily are not recommended.Child: >6 yr: 25 mg/kg tid.May be taken with or without food.
Dosage of Kelfer 250 mg
In adults and children over 6 years: this medicine may be given by mouth in doses of 25mg/kg three times daily. Doses above 100mg/kg daily are not recommended. Or, as directed by the registered physician.
Interaction of Kelfer 250 mg
The safety of concurrent use of Kelfer 250 mg and Vitamin C has not been formally studied. Based on the reported adverse interaction that can occur between deferoxamine and Vitamin C, caution should be used when administering concurrent Kelfer 250 mg and Vitamin C. It should not be given with aluminium containing antacids.
Contraindications
It is contraindicated for hypersensitivity to the active substance or any of the excipients.
Side Effects of Kelfer 250 mg
Gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during Kelfer 250 mg treatment and may require temporary reduction in dose. A reddish brown discoloration of the urine is also common. Other adverse effects that have been reported include arthralgia and increased liver enzymes.
Pregnancy & Lactation
Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Precautions & Warnings
Kelfer 250 mg has been shown to cause neutropenia including agranulocytosis. The patients neutrophil count should be monitored every week. Caution is advised in patients with hepatic or renal impairment.
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Drug Classes
Antidote preparations
Mode Of Action
Kelfer 250 mg is a chelating agent with an affinity for ferric ion (iron III). Kelfer 250 mg binds with ferric ions to form neutral 3:1 (Kelfer 250 mg:iron) complexes that are stable over a wide range of pH values. Kelfer 250 mg has a lower binding affinity for other metals such as copper, aluminum and zinc than for iron.
Pregnancy
Kelfer 250 mg is not recommended for use in pregnant & lactating women.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.
